Published in Hepatitis Weekly, August 23rd, 2004
The multinational APRICOT (AIDS PEGASYS Ribavirin International Coinfection Trial) study found that the drug combination of Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) was much more effective than the previous generation of hepatitis C therapy standard interferon and ribavirin. Efficacy was measured as the sustained virological response (SVR) rate, which is defined by the absence of detectable HCV RNA in the serum for at least 6 months...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.